Hexylresorcinol is an antiseptic compound first introduced for medical use in the early 1920s. It was developed and adopted primarily for its antimicrobial and mild local anesthetic properties, especially in topical preparations and oral health products such as throat lozenges. Unlike antiretroviral drugs such as Abacavir, Hexylresorcinol is not used to treat systemic viral infections like HIV/AIDS and does not function as a nucleoside reverse transcriptase inhibitor. Instead, its mechanism of action is based on disrupting microbial cell membranes and reducing local irritation at the site of application. By the 1940s–1960s, its use had expanded into a variety of over-the-counter formulations, particularly for sore throat relief and oral antisepsis.
BRAND NAMES
Hexylresorcinol does not have any standalone brand names because it is an active ingredient rather than a branded drug. It is used in some skincare products and throat lozenges, but always as part of a formulation, not sold under its own brand name.
MECHANISM OF ACTION
Hexylresorcinol is a phenolic antiseptic that works by denaturing proteins and disrupting the cell membranes of bacteria and fungi, leading to leakage of cellular contents and cell death. In addition, it has a mild local anesthetic effect, which reduces sensory nerve activity and helps relieve pain and irritation in the throat. It may also provide a slight anti-inflammatory effect, contributing to soothing of inflamed mucous membranes.
PHARMACOKINETICS
Absorption
Hexylresorcinol is poorly absorbed from the gastrointestinal tract and mucous membranes when used in lozenges. Its action is mainly local in the oral and throat tissues, where it exerts antiseptic and soothing effects. Only a small amount may be systemically absorbed, and any absorbed portion is rapidly metabolized and excreted, resulting in minimal systemic effects.
Distribution
The volume of distribution (Vd) of hexylresorcinol is not well defined, as the drug undergoes minimal systemic absorption and primarily acts locally in the oral and throat mucosa. Therefore, its distribution into body tissues is insignificant and not clinically relevant.
Metabolism
Hexylresorcinol undergoes limited systemic metabolism because only a small amount is absorbed. The absorbed fraction is mainly metabolized in the liver through conjugation reactions (such as glucuronidation and sulfation), converting it into more water-soluble metabolites.
Elimination
Hexylresorcinol is eliminated mainly via the kidneys after hepatic metabolism. The small absorbed fraction is excreted in urine as conjugated metabolites (such as glucuronides and sulfates). Because systemic absorption is minimal, elimination is rapid and not clinically significant.
PHARMACODYNAMICS
Hexylresorcinol acts locally as an antiseptic by denaturing proteins and disrupting microbial cell membranes, leading to cell death. It also has a mild local anesthetic effect, which reduces sensory nerve activity and relieves throat pain and irritation, along with a slight soothing anti-inflammatory action.
ADMINISTRATION
Hexylresorcinol is administered mainly by the topical route, most commonly as lozenges (sucking tablets) for sore throat. It acts locally on the oral and pharyngeal mucosa. It is not given systemically, as its purpose is to provide local antiseptic and mild analgesic effects in the throat area.
DOSAGE AND STRENGTH
Hexylresorcinol is commonly available in lozenges (throat tablets) with a strength of about 2.4 mg to 4 mg per lozenge (may vary by brand and formulation). The usual dosage is 1 lozenge to be slowly dissolved in the mouth every 2–3 hours as needed, without exceeding the recommended daily limit as specified on the product label. It is intended for local relief of sore throat and oral irritation.
DRUG INTERACTIONS
Hexylresorcinol has minimal clinically significant drug interactions because it is used topically in lozenges and has very low systemic absorption. However, theoretically, it may show additive irritant or drying effects if used with other local antiseptics or throat medications. Caution is advised when combining multiple lozenges or mouth preparations, as this may increase mucosal irritation. Overall, important drug–drug interactions are rare and not well documented.
FOOD INTERACTIONS
Hexylresorcinol has no significant food interactions due to its local action and minimal systemic absorption. However, eating or drinking soon after taking a lozenge may reduce its effectiveness, so it is best to avoid food or beverages for a short time after use.
CONTRAINDICATIONS
Hexylresorcinol is generally well tolerated, but it is contraindicated in patients with hypersensitivity or allergy to hexylresorcinol or any component of the formulation. It should be avoided in individuals who develop severe mouth irritation or allergic reactions during use. It is also not recommended for very young children unless advised by a healthcare professional.
SIDE EFFECTS
Oral irritation
Burning sensation in mouth or throat
Dry mouth
Altered taste
Rare allergic reactions (rash, itching, swelling)
OVER DOSE
Rare due to local use (lozenges)
Excess intake may cause nausea, vomiting, abdominal discomfort
Mouth and throat irritation
Possible dizziness or headache in severe cases
TOXICITY
Hexylresorcinol has low toxicity because it is mainly used locally with minimal systemic absorption. Toxic effects are rare but may include gastrointestinal irritation, mouth and throat irritation, and occasional dizziness or headache if taken in large amounts. Severe toxicity is uncommon, and treatment is supportive and symptomatic.
